Robert Luxenhofer completed his PhD in 2007 at the TU München in polymer chemistry developing a novel polymer functionalization approach since developed further by Serina Therapeutics to introduce the first-in-human poly(2-oxazoline)-drug conjugates. As a postdoc with Alexander V. Kabanov at the University of Nebraska Medical Center, he discovered ultra-high loaded drug formulations and investigated structure dependent endocytosis of polymer amphiphiles. Returning to Germany in 2009, he started to investigate polysarcosine and polypeptoids as biomaterials at the TU Dresden. In 2012, he joined the Julius-Maximilians Universität as an Associate Professor, where he continued working on polypeptoids and ultra-high drug formulations, but also started investigating biofabrication and 3D printing using melt electrowriting. In 2019, he joined the University of Helsinki as a Full Professor. He holds 7 patents and is co-founder of two companies focusing on developing novel polymers for medical applications.